AT442841T - nanoparticles pegylated - Google Patents

nanoparticles pegylated

Info

Publication number
AT442841T
AT442841T AT05745586T AT05745586T AT442841T AT 442841 T AT442841 T AT 442841T AT 05745586 T AT05745586 T AT 05745586T AT 05745586 T AT05745586 T AT 05745586T AT 442841 T AT442841 T AT 442841T
Authority
AT
Austria
Prior art keywords
nanoparticles pegylated
pegylated
nanoparticles
Prior art date
Application number
AT05745586T
Other languages
German (de)
Inventor
Garreta Juan Manuel Irache
Krassimira Pavlova Yoncheva
Original Assignee
Inst Cientifico Tecnol Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200401022A priority Critical patent/ES2246694B1/en
Application filed by Inst Cientifico Tecnol Navarra filed Critical Inst Cientifico Tecnol Navarra
Priority to PCT/ES2005/000226 priority patent/WO2005104648A2/en
Publication of AT442841T publication Critical patent/AT442841T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/04Anhydrides, e.g. cyclic anhydrides
    • C08F222/06Maleic anhydride
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
AT05745586T 2004-04-29 2005-04-28 nanoparticles pegylated AT442841T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200401022A ES2246694B1 (en) 2004-04-29 2004-04-29 Pegylated Nanoparticles.
PCT/ES2005/000226 WO2005104648A2 (en) 2004-04-29 2005-04-28 Pegylated nanoparticles

Publications (1)

Publication Number Publication Date
AT442841T true AT442841T (en) 2009-10-15

Family

ID=35242088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05745586T AT442841T (en) 2004-04-29 2005-04-28 nanoparticles pegylated

Country Status (13)

Country Link
US (1) US8628801B2 (en)
EP (1) EP1752142B1 (en)
JP (1) JP2007534729A (en)
CN (1) CN1976688A (en)
AT (1) AT442841T (en)
AU (1) AU2005237270B2 (en)
BR (1) BRPI0509827A (en)
CA (1) CA2564982C (en)
DE (1) DE602005016674D1 (en)
ES (2) ES2246694B1 (en)
MX (1) MXPA06012583A (en)
RU (1) RU2400215C2 (en)
WO (1) WO2005104648A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
ES2310122B1 (en) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticles comprising a cyclodextrin and a biologically active molecule and its applications.
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
ES2358493B1 (en) * 2008-04-05 2012-06-13 Instituto Cientifico Y Tecnologico De Navarra, S.A Pegylated nanoparticles comprising a biologically active molecule and its applications.
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
RU2013120302A (en) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Engineered nucleic acids and methods for their use
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
EP2804632A1 (en) 2012-01-19 2014-11-26 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
MX2014007233A (en) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
JP6138904B2 (en) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー Non linear multi-block copolymers drug conjugates for the delivery of active agent
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013256130B2 (en) 2012-05-03 2017-12-21 Johns Hopkins University, The Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
CA2900652A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015020139A2 (en) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compounds and therapeutic uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN103483576B (en) * 2013-08-16 2015-04-08 辽宁鑫隆科技有限公司 Method for producing cane sugar modified polyether
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods for making and using the same
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN108530458A (en) 2013-11-01 2018-09-14 卡拉制药公司 Crystalline forms of therapeutic compounds and uses thereof
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
CN106659803A (en) 2014-04-23 2017-05-10 摩登纳特斯有限公司 Nucleic acid vaccines
WO2016087340A1 (en) 2014-12-01 2016-06-09 Innoup Farma, S.L. Nanoparticles for encapsulating compounds, the preparation and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2608988B1 (en) 1986-12-31 1991-01-11 Centre Nat Rech Scient systems process for preparing colloidal dispersible of a substance in the form of nanoparticles
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
SE8900422D0 (en) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler and foerfarande Foer framstaellning of these
TW209174B (en) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1247472B (en) * 1991-05-31 1994-12-17 Fidia Spa Process for the preparation of microspheres containing biologically active components.
AU636544B1 (en) 1991-11-27 1993-04-29 Lignyte Co., Ltd. Water insoluble biocompatible hyaluronic acid polyion complex and method of making the same
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US20010053359A1 (en) * 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
HUT76846A (en) 1994-08-30 1997-12-29 Hyal Pharma Corp Hyaluronic acid and derivatives for modulation of cellular activity
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
ES2098188B1 (en) 1995-05-11 1997-12-16 Univ Santiago Compostela Development of nanoparticles based on hydrophilic polymers.
PT752245E (en) * 1995-07-05 2002-09-30 Europ Economic Community Biocompatible and biodegradable nanoparticles for the absorption and administration of proteinaceal drugs
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
ES2114502B1 (en) 1996-07-29 1999-07-01 Univ Santiago Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms.
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
AU9799198A (en) 1997-10-09 1999-05-03 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
DE19810965A1 (en) 1998-03-13 1999-09-16 Aventis Res & Tech Gmbh & Co Nanoparticles comprising polyelectrolyte complex of polycation, polyanion and biologically active agent, especially useful for controlled drug release on oral administration
FR2777193B1 (en) * 1998-04-14 2001-06-08 Coletica Particle hydroxamic chelating group of metal ions and their use in cosmetics or pharmacy
JPH11302199A (en) * 1998-04-16 1999-11-02 Sankyo Co Ltd Drug carrier composed of graft copolymer
FR2777895A1 (en) * 1998-04-28 1999-10-29 Debio Rech Pharma Sa Non crosslinked block polymer useful as support for active agents e.g. antigens and vaccines
IN191203B (en) * 1999-02-17 2003-10-04 Amarnath Prof Maitra A process for preparation of pharmaceutical composition of paclitaxol entrapped into a polymeric micelles nanoparticles
AU4476600A (en) * 1999-04-22 2000-11-10 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
JP4703926B2 (en) 1999-10-15 2011-06-15 ジェネティクス インスティテュート,エルエルシー The formulation of hyaluronic acid for delivering a bone morphogenetic protein
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
AU6259601A (en) 2000-05-03 2001-11-12 Natural As Compositions containing aminopolysaccharides and negatively charged polysaccharides
KR100375299B1 (en) 2000-10-10 2003-03-10 주식회사 엘지생명과학 Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods
AU2002220002B2 (en) * 2000-10-31 2006-12-14 Evonik Corporation Methods and compositions for enhanced delivery of bioactive molecules
ES2178961B1 (en) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Based nanoparticle fabrication of vinyl methyl ether and maleic anhydride for drug delivery of hydrophilic nature, particularly purine and pyrimidine bases.
ES2221530B1 (en) 2002-07-19 2006-02-16 Universidad De Santiago De Compostela Nanoparticles for the administration of active ingredients, process for the preparation of said particles and composition containing them.
AT428730T (en) 2003-08-12 2009-05-15 Octapharma Ag A process for preparing an alpha-1- antitrypsinlösung
ES2246695B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composition stimulatory immune response comprising nanoparticles based on a copolymer of methyl vinyl ether and maleic anhydride.

Also Published As

Publication number Publication date
WO2005104648A3 (en) 2005-12-08
JP2007534729A (en) 2007-11-29
DE602005016674D1 (en) 2009-10-29
AU2005237270B2 (en) 2011-02-17
EP1752142A2 (en) 2007-02-14
US20080248125A1 (en) 2008-10-09
ES2246694A1 (en) 2006-02-16
BRPI0509827A (en) 2007-10-23
RU2006142100A (en) 2008-06-20
ES2333659T3 (en) 2010-02-25
EP1752142B1 (en) 2009-09-16
WO2005104648A2 (en) 2005-11-10
CA2564982A1 (en) 2005-11-10
CN1976688A (en) 2007-06-06
US8628801B2 (en) 2014-01-14
ES2246694B1 (en) 2007-05-01
MXPA06012583A (en) 2007-03-21
AU2005237270A1 (en) 2005-11-10
CA2564982C (en) 2015-04-21
RU2400215C2 (en) 2010-09-27

Similar Documents

Publication Publication Date Title
AT539708T (en) Wirbelfazettengelenkprothese
AT536418T (en) Lipidverkapselte interference-rna
AT543462T (en) Allo-implant
AT462363T (en) Polyaxialpedikelschraubenanordung
DE602005014923D1 (en) Teilchenbestrahlungssystem
DE602005011437D1 (en) Brombeerextrakt
AT381540T (en) Oximesther-photoinitiators
DE602005015457D1 (en) Ungselements
DE602004014644D1 (en) Teantrieb
DE602005011251D1 (en) Zettenvorrichtung
DE602004011270D1 (en) Auslasszusatzmodul
DE602005011516D1 (en) Nähfadenankereinführungssystem
DE602005000941D1 (en) Sicherheitsdauerverweilnadel
AT415112T (en) Abschminkapplikator
AT473021T (en) Nichtkräuselnde polyhydroxyalkanoatnähte
AT447853T (en) Enyzmgranulat
DE602004025621D1 (en) Stentreduziersystem
AT455498T (en) Zenteseinstrument
AT538176T (en) Polymilchsäureharzzusammensetzung
DE602005002234D1 (en) Mq-t propylsiloxanharze
DE602004032477D1 (en) Ragglieds
DE602005013789D1 (en) -eingabeabtastung
AT526869T (en) Hydratationsmonitor
AT535227T (en) Selbsterwärmendes rasierschaumprodukt
AT442115T (en) Unterkiefervorschiebeorthese

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties